Status:
COMPLETED
Zometa for the Management of Tumor-induced Hypercalcemia and Malignant Bone Pain in the Community
Lead Sponsor:
Alberta Health services
Conditions:
Cancer
Hypercalcemia
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Treatment in the home and hospice of long-term care facilities, particularly for non-ambulatory patients, could provide significant advantages for patients and for the region. The Calgary Health Regio...
Detailed Description
Treatment in the home and hospice of long-term care facilities, particularly for non-ambulatory patients, could provide significant advantages for patients and for the region. The Calgary Health Regio...
Eligibility Criteria
Inclusion
- If hypercalcemic:
- Serum corrected Ca+++\>= 2.5 mmol/L and symptomatic hypercalcemia
- Asymptomatic hypercalcemia with corrected Ca+++\>= 3.0 mmol/L
- Moderate to severe intolerable pain (\>=6/10 on numerical rating scale \[NRS\]) despite optimal treatments with a strong opioid such as morphine, hydromorphone, fentanyl, oxycodone or methadone
- Radiotherapy bone pain related to metastatic bone disease
Exclusion
- Not on a regular bisphosphonate regimen
Key Trial Info
Start Date :
January 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2006
Estimated Enrollment :
11 Patients enrolled
Trial Details
Trial ID
NCT00126386
Start Date
January 1 2004
End Date
September 1 2006
Last Update
November 21 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tom Baker Cancer Centre
Calgary, Alberta, Canada, T2N 4N2